Lydia Tsai
Director - Business Development & Companion Diagnostics Bio-Techne Corporation
Seminars
Monday 22nd September 2025
Beyond One-Size-Fits-All: Moving from Rigid Partnerships to Dynamic IVD Collaborations
4:10 pm
- Navigating multiple clinical objectives and biomarker strategies requires a flexible diagnostic partner equipped with a comprehensive range of technologies
- The ideal partner should be experienced in oncology diagnostics with established infrastructure for developing tests such as ESR1 LBx and BCR-ABL
- Leveraging a trusted IVD company ensures essential expertise, reliability, and globally accessible CDx and clinical assay development solutions
